Literature DB >> 17095142

Histologic grading of noninvasive papillary urothelial neoplasms.

Gregory T MacLennan1, Ziya Kirkali, Liang Cheng.   

Abstract

OBJECTIVES: In 1998, a revised system of classifying noninvasive papillary urothelial neoplasms of the urinary bladder was proposed and subsequently formally adopted by the World Health Organization (WHO). The introduction of this new system was justified as being potentially superior on a number of levels to the 1973 WHO classification system that it replaced. Specifically, a new category of neoplasms, designated papillary urothelial neoplasm of low malignant potential (PUNLMP), was considered advantageous for several reasons. The new system was expected to gain widespread acceptance, improve reproducibility of diagnoses among pathologists, and enhance the correlation between urine cytology and tumor histology. We examine the history of the changes in terminology for these lesions, the relative merits of PUNLMP terminology, the extent to which the expectations accompanying the new grading system have been met, and the extent to which the new system has enhanced the management of patients with noninvasive papillary urothelial neoplasms of the bladder.
METHODS: A PubMed literature search after the introduction of this new classification was performed and relevant papers reviewed. RESULTS AND
CONCLUSIONS: The 2004 WHO classification is a positive initiative in attempting to standardize urothelial tumor grading by expanding and clearly defining the morphologic characteristics of noninvasive papillary urothelial neoplasms. The new terminology used in this system is of questionable validity and utility. Full-genome searches for prognostic and predictive molecular gene expression signatures, GeneChip technology and proteomics techniques, and several new biomarkers and molecular tests may be useful in future grading schemes after their clinical utility is better established.

Entities:  

Mesh:

Year:  2006        PMID: 17095142     DOI: 10.1016/j.eururo.2006.10.037

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  33 in total

1.  MCM2 and MCM5 as prognostic markers in colon cancer: a worthwhile approach.

Authors:  Maximilian Burger
Journal:  Dig Dis Sci       Date:  2008-08-21       Impact factor: 3.199

2.  Bladder cancer: Progress in defining progression in NMIBC.

Authors:  Michael Gierth; Maximilian Burger
Journal:  Nat Rev Urol       Date:  2013-11-26       Impact factor: 14.432

3.  SIU-ICUD on bladder cancer: pathology.

Authors:  Eva Compérat; Marek Babjuk; Ferran Algaba; Mahul Amin; Fadi Brimo; David Grignon; Donna Hansel; Ondra Hes; Bernard Malavaud; Victor Reuter; Theo van der Kwast
Journal:  World J Urol       Date:  2018-09-14       Impact factor: 4.226

4.  Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guérin immunotherapy?

Authors:  Thomasz Golabek; Joan Palou; Oscar Rodríguez; Josep Maria Gaya; Alberto Breda; Humberto Villavicencio
Journal:  World J Urol       Date:  2016-06-09       Impact factor: 4.226

5.  Reproductibilité des classifications OMS 1973 et OMS 2004 des tumeurs urothéliales papillaires de la vessie.

Authors:  Soumaya Ben Abdelkrim; Soumaya Rammeh; Amel Trabelsi; Lilia Ben Yacoub-Abid; Nabil Ben Sorba; Lilia Jaïdane; Moncef Mokni
Journal:  Can Urol Assoc J       Date:  2011-09-08       Impact factor: 1.862

6.  Histologic grading of urothelial papillary neoplasms: impact of combined grading (two-numbered grading system) on reproducibility.

Authors:  Burçin Tuna; Kutsal Yörükoglu; Ender Düzcan; Sait Sen; Nalan Nese; Banu Sarsık; Aysegul Akder; Sehnaz Sayhan; Uğur Mungan; Ziya Kirkali
Journal:  Virchows Arch       Date:  2011-04-12       Impact factor: 4.064

7.  Development and external validation of a nomogram to predict high-grade papillary bladder cancer before first-time transurethral resection of the bladder tumor.

Authors:  Ken Wakai; Takanobu Utsumi; Kei Yoneda; Ryo Oka; Takumi Endo; Masashi Yano; Masaaki Fujimura; Naoto Kamiya; Nobuyuki Sekita; Kazuo Mikami; Isamu Sugano; Nobuyuki Hiruta; Hiroyoshi Suzuki
Journal:  Int J Clin Oncol       Date:  2018-05-26       Impact factor: 3.402

8.  Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications.

Authors:  Bas W G van Rhijn; Mireia Musquera; Liyang Liu; André N Vis; Tahlita C M Zuiverloon; Geert J L H van Leenders; Wim J Kirkels; Ellen C Zwarthoff; Egbert R Boevé; Adriaan C Jöbsis; Bharati Bapat; Michael A S Jewett; Alexandre R Zlotta; Theo H van der Kwast
Journal:  Mod Pathol       Date:  2014-11-28       Impact factor: 7.842

9.  Mismatch repair hMSH2, hMLH1, hMSH6 and hPMS2 mRNA expression profiles in precancerous and cancerous urothelium.

Authors:  Dimitra P Vageli; Stavros Giannopoulos; Sotirios G Doukas; Christos Kalaitzis; Stilianos Giannakopoulos; Alexandra Giatromanolaki; George K Koukoulis; Stavros Touloupidis
Journal:  Oncol Lett       Date:  2012-10-19       Impact factor: 2.967

Review 10.  Reproducibility and reliability of tumor grading in urological neoplasms.

Authors:  Rainer Engers
Journal:  World J Urol       Date:  2007-09-09       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.